Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sagar Lonial

Showing results (201-210 of 440) with videos related to

Pageof 44
Sort By:
American Heart Journal|June 23, 2009
Bone marrow mobilization with granulocyte macrophage colony-stimulating factor improves endothelial dysfunction and exercise capacity in patients with peripheral arterial diseaseVeerappan Subramaniyam, Edmund K Waller, Jonathan R Murrow, et al.
Transfusion|February 22, 2011
A randomized clinical trial comparing granulocyte-colony-stimulating factor administration sites for mobilization of peripheral blood stem cells for patients with hematologic malignancies undergoing autologous stem cell transplantationHeather Renfroe, Mike Arnold, Louette Vaughn, et al.
Expert Review of Anticancer Therapy|June 9, 2015
Panobinostat: a novel pan-deacetylase inhibitor for the treatment of relapsed or relapsed and refractory multiple myelomaPaul G Richardson, Jacob P Laubach, Sagar Lonial, et al.
Blood Cancer Journal|September 13, 2024
Quadruplet therapy for newly diagnosed myeloma: comparative analysis of sequential cohorts with triplet therapy lenalidomide, bortezomib and dexamethasone (RVd) versus daratumamab with RVD (DRVd) in transplant-eligible patientsNisha S Joseph, Jonathan L Kaufman, Vilas A Gupta, et al.
Transfusion|March 27, 2007
Optimizing the timing of chemotherapy for mobilizing autologous blood hematopoietic progenitor cellsMichelle L Hicks, Sagar Lonial, Amelia Langston, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2012
Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myelomaSagar Lonial, Ravi Vij, Jean-Luc Harousseau, et al.
Blood|August 17, 2013
PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myelomaPaul G Richardson, Robert L Schlossman, Melissa Alsina, et al.
Cancer|September 12, 2018
Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 4-year follow-up and analysis of relative progression-free survival from the randomized ELOQUENT-2 trialMeletios A Dimopoulos, Sagar Lonial, Keith A Betts, et al.
Blood|September 16, 2011
Bortezomib-induced "BRCAness" sensitizes multiple myeloma cells to PARP inhibitorsPaola Neri, Li Ren, Kathy Gratton, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 14, 2010
Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's diseaseFrits van Rhee, Luis Fayad, Peter Voorhees, et al.
Pageof 44

Showing results (201-210 of 440) with videos related to

Sort By:
Pageof 44
American Heart Journal|June 23, 2009
Bone marrow mobilization with granulocyte macrophage colony-stimulating factor improves endothelial dysfunction and exercise capacity in patients with peripheral arterial diseaseVeerappan Subramaniyam, Edmund K Waller, Jonathan R Murrow, et al.
Transfusion|February 22, 2011
A randomized clinical trial comparing granulocyte-colony-stimulating factor administration sites for mobilization of peripheral blood stem cells for patients with hematologic malignancies undergoing autologous stem cell transplantationHeather Renfroe, Mike Arnold, Louette Vaughn, et al.
Expert Review of Anticancer Therapy|June 9, 2015
Panobinostat: a novel pan-deacetylase inhibitor for the treatment of relapsed or relapsed and refractory multiple myelomaPaul G Richardson, Jacob P Laubach, Sagar Lonial, et al.
Blood Cancer Journal|September 13, 2024
Quadruplet therapy for newly diagnosed myeloma: comparative analysis of sequential cohorts with triplet therapy lenalidomide, bortezomib and dexamethasone (RVd) versus daratumamab with RVD (DRVd) in transplant-eligible patientsNisha S Joseph, Jonathan L Kaufman, Vilas A Gupta, et al.
Transfusion|March 27, 2007
Optimizing the timing of chemotherapy for mobilizing autologous blood hematopoietic progenitor cellsMichelle L Hicks, Sagar Lonial, Amelia Langston, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2012
Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myelomaSagar Lonial, Ravi Vij, Jean-Luc Harousseau, et al.
Blood|August 17, 2013
PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myelomaPaul G Richardson, Robert L Schlossman, Melissa Alsina, et al.
Cancer|September 12, 2018
Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 4-year follow-up and analysis of relative progression-free survival from the randomized ELOQUENT-2 trialMeletios A Dimopoulos, Sagar Lonial, Keith A Betts, et al.
Blood|September 16, 2011
Bortezomib-induced "BRCAness" sensitizes multiple myeloma cells to PARP inhibitorsPaola Neri, Li Ren, Kathy Gratton, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 14, 2010
Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's diseaseFrits van Rhee, Luis Fayad, Peter Voorhees, et al.
Pageof 44